

BioNovelus
Income Statement

	For the Three Months Ended June 30,2015	For the Twelve Months Ended September 30,2014
Revenue	\$ -	\$ -
Expenses		
Travel	\$ 8,100.00	\$ -
Advertising & Promotion	\$ 213.60	\$ -
Bank Fees	\$ 74.92	\$ -
Licenses & Permit	\$ 50.00	\$ -
Consulting Fees	\$ 10,651.08	\$ -
Mail Service	\$ 401.00	\$ -
Meal & Entertainment	\$ 212.61	\$ 195,875.00
Grant Fees	\$ 750.00	
SCC & OTC Filing	\$ 10,148.58	
Taxes	\$ 13.76	
Total Expenses	\$ 30,615.55	\$ 195,875.00
Loss from Continuing Operations	\$ 30,615.55	\$ (195,875.00)
Other Income (Expenses)		
	\$ -	\$ -
Total Other Income (Expenses)	\$ -	\$ -
Net Loss	\$ 30,615.55	\$ (195,875.00)

BioNovelus
Balance Sheet

	For the Three Months Ended June 30,2015	For the Twelve Months Ended September 30,2014
Assets		
Cash	\$ 7,689.00	\$ 100.00
Accounts Receivable	\$ 3,600.00	\$ 15,511.00
Intellectual Property	\$ 24,600.00	\$ 29,632.00
Property & Equipment - Research	\$ 1,698,140.00	\$ -
Prepaid expenses	\$ 550,000.00	\$ -
Less Depreciation	\$ (1,095,210.74)	
Total Assets	<u>\$ 1,188,818.26</u>	<u>\$ 45,243.00</u>
Liabilities and Shareholder's Deficiency		
Accounts Payable	\$ 4,182.00	\$ 957.00
Accrued director fees	\$ 637,500.00	\$ 510,000.00
Accrued legal fees	\$ -	\$ -
Current Liabilities of discontinued operations		
Loan payable to officers	\$ 24,043.26	\$ -
Loan payable to officers		
Notes payable-Promissory Notes	\$ 361,637.00	\$ 575,514.00
Total Liabilities	<u>\$ 1,027,362.26</u>	<u>\$ 1,086,471.00</u>
Preferred stock, \$.001 par value,10,000,000 shares authorized; 9,800,000. shares issued and outstanding	\$ 10,000.00	\$ 10,000.00
Common stock, \$.001 par value 500,000.000 shares authorized and 86,917,656 shares and 70,116,467 shares issued and outstanding as of June 30, 2015 and Sept 30,2014 respectively,	\$ 70,116.00	\$ 86,918.00
Additional paid in capital	\$ 2,829,231.00	\$ 2,829,231.00
Accumulated Deficit	\$ (2,747,891.00)	\$ (4,057,863.00)
Total Shareholders's Equity	<u>\$ 161,456.00</u>	<u>\$ (1,131,714.00)</u>
Total Liabilities and Shareholders Equity	<u>\$ 1,188,818.26</u>	<u>\$ (45,243.00)</u>

See Accompanying notes

BioNovelus**Statement of StockHolders Equity**

	Preferred Stock		Common Stock		Additional Paid in Capital	Retained Earnings Accumulated deficit	Total
Balance , March 30,2015	10,000,000.00	10,000.00	86,917,656.00	86,918.00	2,829,231.00	(3,181,843.00)	(255,694.00)
Return to Treasury - Stock Split			-86,801,765	-86801			
Issued From Treasury - Acquisition			70,000,000.00	70,000.00			
Issued from Treasury - Rounding			576.00	-			
Balance, June 30, 2015	10,000,000.00	10,000.00	70,116,467.00	70,117.00	2,829,231.00	(2,747,891.00)	1,188,818.26

BioNovelus
Statement of Cash Flows

	For the Three Months Ended June 30,2015	For the Twelve Months Ended September 30,2014
Cash Flows from operating and activities of discounted operations		
Net Loss	\$ (281.00)	\$ (35,919.00)
Adjustments to reconcile net loss to net cash Used in) provided by operating activies		
Accounts Payable	\$ -	\$ (127,513.00)
Current Liability	\$ -	\$ -
Accrued Expenses	\$ -	\$ -
Accounts Receivable	\$ -	\$ (13,375.00)
Note payable-Officer	\$ -	\$ -
Net cash(used) provided by operating activites	\$ (281.00)	\$ (176,807.00)
Cash flows from investing activites of discounted operations		
Purchase of property and equipment	\$ -	\$ -
Net cash used in investing activities	\$ -	\$ -
Preferred stock	\$ -	\$ -
Common Stock	\$ -	\$ -
Additional Paid-in capital	\$ -	\$ -
Repayments of long-term debt to equity	\$ 185,875.00	\$ 176,807.00
Net cash provided by (used in) financing activies	\$ 185,875.00	\$ 176,807.00
Net (Decrease) increase in cash	\$ -	\$ -
Cash at beginning of period	\$ -	\$ -
Cash at end of period	\$ -	\$ -